AU 011

Drug Profile

AU 011

Alternative Names: AU-011

Latest Information Update: 27 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aura Biosciences; National Cancer Institute (USA)
  • Developer Aura Biosciences
  • Class Antineoplastics; Drug conjugates; Eye disorder therapies
  • Mechanism of Action Immunostimulants; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Uveal melanoma

Most Recent Events

  • 23 Jul 2018 Aura Biosciences plans a phase III trial for Uveal melanoma in USA and Europe
  • 23 Jul 2018 Aura Biosciences plans to complete enrolment in its phase Ib/II trial for Uveal melanoma in October 2018
  • 17 Jun 2018 Safety and efficacy data from phase Ib/II trial in Uveal melanoma released by Aura Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top